PIM
UBX

Partner Investment Management’s Unity Biotechnology UBX Stock Holding History

Partner Investment Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-596
Closed -$48K – 96
2019
Q1 		$48K Sell
596
-30,277
-98% -$3.43M 0.06% 88
2018
Q4 		$5.02M Hold
30,873
– – 6.27% 1
2018
Q3 		$4.48M Sell
30,873
-3
-0% -$494 3.43% 3
2018
Q2 		$4.08M Buy
+30,876
New +$4.51M 3.29% 3

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Partner Investment Management's UBX Position: Q2 2019 in Review

Partner Investment Management sold out of Unity Biotechnology (UBX) in Q2 2019, closing a stake of 596 shares — an estimated $48K sold.

Partner Investment Management first reported a position in UBX in Q2 2018 and held it in 4 quarters. The position peaked at $5.02M in Q4 2018. 58 funds tracked by Wall St. Rank hold UBX as of Q2 2019.

  • Partner Investment Management reported no remaining Unity Biotechnology position as of Q2 2019 after selling out during the quarter.
  • Partner Investment Management sold 596 Unity Biotechnology shares in Q2 2019, an estimated $48K.
  • Partner Investment Management first reported a position in Unity Biotechnology in Q2 2018 and held it in 4 quarters.
  • Partner Investment Management's Unity Biotechnology position peaked at $5.02M in Q4 2018.
  • 58 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2019.

Based on Partner Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.